KL-A167

Phase 3Small molecule

SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

KL-A167 is one of 158 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

157

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

LymphomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

KL-A167

SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3

1 2

Trodelvy

Gilead

Preclinical

37 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 6

Spravato

WWim Janssens

Preclinical

2 7

Tricor

JJagotec

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Bisphosphonate

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Breast Cancer

NCT05445908

Q4 2027

Phase 3Active, not recruiting

Nasopharyngeal Carcinoma

NCT05294172

Q4 2029

Phase 2Not yet recruiting

Small Cell Lung Cancer

NCT07296809

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma2 trials

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT05294172·295 enrolled

KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

Completed·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT03848286·153 enrolled

Breast Cancer1 trial

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT05445908·175 enrolled

Not yet recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07296809·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for KL-A167. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KL-A167 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KL-A167. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

KL-A167

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q4 2029

Trials by Indication[1]

Nasopharyngeal Carcinoma2 trials

Breast Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Lymphoma1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News